ADMA Biologics, Inc. (ADMA)
| Market Cap | 2.12B -46.0% |
| Revenue (ttm) | 512.28M +8.0% |
| Net Income | 168.96M -19.1% |
| EPS | 0.70 -17.0% |
| Shares Out | 223.98M |
| PE Ratio | 13.49 |
| Forward PE | 10.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,383,259 |
| Open | 9.47 |
| Previous Close | 9.54 |
| Day's Range | 9.32 - 9.51 |
| 52-Week Range | 7.21 - 20.46 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 17.00 (+79.89%) |
| Earnings Date | Aug 5, 2026 |
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal anti... [Read more]
Financial Performance
In 2025, ADMA Biologics's revenue was $510.17 million, an increase of 19.63% compared to the previous year's $426.45 million. Earnings were $146.93 million, a decrease of -25.67%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ADMA stock is "Buy." The 12-month stock price target is $17.0, which is an increase of 79.89% from the latest price.
News
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
PHILADELPHIA, Sept. 8, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biol...
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
Philadelphia, Pennsylvania--(Newsfile Corp. - August 24, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into potential breaches of fiduciary duty by the Board of D...
Adma Biologics reports Q2 EPS 16c, consensus 16c
Reports Q2 revenue $124.4M, consensus $125.36M. “Our second quarter results reflect strong execution across the business and demonstrate the power of ASCENIV’s growth trajectory,” said Adam Grossman, ...
Adma Biologics backs FY26 revenue view $530M-$560M, consensus $534.37M
Backs FY26 adjusted EBITDA view $265M-$300M. The company said, “The FY2026 outlook continues to reflect sustained competitive dynamics and pricing pressure within the U.S. immune globulin market throu...
ADMA Biologics Earnings Call Transcript: Q2 2026
Q2 2026 saw strong ASCENIV growth, robust cash generation, and margin expansion, with ASCENIV revenue up 24% year-over-year and BIVIGAM stabilizing. Full-year guidance was reiterated, share repurchases continued, and SG-001 development advanced.
ADMA Biologics Earnings release: Q2 2026
ADMA Biologics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
ADMA Biologics Quarterly report: Q2 2026
ADMA Biologics has published its Q2 2026 quarterly earnings report on August 5, 2026.
ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update
2Q 2026 Total Revenue of $124.4 Million, Increasing 2% Year-over-Year 2Q 2026 ASCENIV Revenue of $102.9 Million, Increasing 24% Year-over-Year BIVIGAM Utilization Stabilized with Sequential Improvemen...
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. , a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for potential ...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA BIOLOGICS, INC. Lawsuit - ADMA
Jerrold V. Grossman, ADMA Biologics co-founder and Vice Chairman, signed annual reports that allegedly concealed channel stuffing and an undisclosed related party distributor operating from ADMA's own...
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J.
Did You Lose Money Investing in ADMA Biologics, Inc. (ADMA)? Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ:...
$ADMA Fraud Notification: ADMA Biologics Sued for Fraud Over Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and ...
Adma Biologics price target lowered to $17 from $20 at Mizuho
Mizuho lowered the firm’s price target on Adma Biologics (ADMA) to $17 from $20 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical device…
$ADMA Fraud Notification: ADMA Biologics Sued for Securities Fraud After Channel Stuffing Claims Spark a 29% Stock Drop – Investors Notified to Contact BFA Law by August 10
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and ...
ADMA INVESTOR REMINDER: ADMA Biologics, Inc. Investors Have Until August 10, 2026 To Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at inves...
ADMA BIOLOGICS, INC. (ADMA) INVESTOR ALERT Investors With Large Losses in ADMA Biologics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Grabar Law Office Investigates ADMA Biologics, Inc. (ADMA) on Behalf of Long-Term Shareholders
Philadelphia, Pennsylvania--(Newsfile Corp. - June 23, 2026) - Grabar Law Office is investigating whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) breached their fiduciary...
20 growth stocks priced as value stocks
A broad screen of U.S. stocks yields a list of companies trading at low valuations to expected earnings, with high projected revenue growth rates through 2028. The list of 20 stocks includes eight fin...
$ADMA Breaking News: ADMA Biologics Sued for Securities Fraud after Channel Stuffing Claims Lead to 16% Stock Drop – Investors Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $ADMA #ADMA--ADMA Biologics Sued for Securities Fraud after Channel Stuffing Claims Lead to 16% Stock Drop – Investors Notified to Contact BFA Law.
Adma Biologics resumed with an Outperform at Raymond James
Raymond James analyst Ryan Deschner resumed coverage of Adma Biologics (ADMA) with an Outperform rating and $21 price target Adma has transformed into a profitable, high-growth company over just the…
ADMA Biologics Investigation: ADMA Biologics (ADMA) Investigated for Alleged Channel Stuffing – Contact BFA Law if You Suffered Losses
NEW YORK, June 10, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the f...
ADMA Legal Claims: ADMA Biologics may have Misrepresented its Revenue Sources to Investors – Contact BFA Law about its Pending Securities Fraud Investigation
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the f...
ADMA Biologics Transcript: AGM 2026
The meeting established quorum and addressed all agenda items, including the election of two directors, ratification of the accounting firm, and approval of executive compensation. All proposals passed with strong support, and no shareholder questions were raised.
$ADMA Securities News: ADMA Biologics Investigated for Securities Fraud Over Channel Stuffing Allegations – Investors with Losses Notified to Contact BFA Law
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the fe...